JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
139.82
-0.07 (-0.05%)
As of 12:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close139.90
Open139.65
Bid139.93 x 1000
Ask139.95 x 800
Day's Range138.86 - 140.14
52 Week Range118.62 - 148.99
Volume2,377,871
Avg. Volume6,629,293
Market Cap372.322B
Beta (3Y Monthly)0.69
PE Ratio (TTM)25.91
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2019-02-25
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer's lightning round: I'm sticking with this gold stock pick
    CNBC Videos18 hours ago

    Cramer's lightning round: I'm sticking with this gold stock pick

    Jim Cramer takes calls and gives his thoughts about different stocks in lightning speed.

  • Checking in on trade war's impact on the markets
    Yahoo Finance Video6 days ago

    Checking in on trade war's impact on the markets

    GuideStone Capital Management President David Spika joins Yahoo Finance's Adam Shapiro, Julie Hyman, Jared Blikre, and MIT Professor Sinan Aral.

  • Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
    Zacks1 hour ago

    Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

    Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

  • Benzinga5 hours ago

    Jim Cramer Gives His Opinion On Barrick Gold, Canopy Growth, EA, Johnson & Johnson And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he likes CarMax, Inc (NYSE: KMX ) in the auto dealerships space, but he will take a closer look at CarGurus Inc (NASDAQ: CARG ). Instead ...

  • Exploring JNJ’s Key Oncology Assets in the First Quarter
    Market Realist5 hours ago

    Exploring JNJ’s Key Oncology Assets in the First Quarter

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Imbruvica’s trendsIn the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in

  • CNBC18 hours ago

    Cramer's lightning round: I'm sticking with this gold stock pick

    It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.CarGurus Inc. CARG : "Well, I gotta tell you my viewers, including you Scott, are smarter than I am.

  • Pharmaceutical Segment: A Key Revenue Driver for JNJ in Q1
    Market Realistyesterday

    Pharmaceutical Segment: A Key Revenue Driver for JNJ in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performanceIn the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide

  • Motley Foolyesterday

    Prescription for Success?

    Prescription drug sales, the future of Hulu, and more.

  • JNJ’s Consumer Business: International Market Trends in Q1
    Market Realistyesterday

    JNJ’s Consumer Business: International Market Trends in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC business performance in international markets In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported a 3% YoY

  • JNJ’s OTC, Oral Care, and Wound Care Businesses: Key Trends in Q1
    Market Realistyesterday

    JNJ’s OTC, Oral Care, and Wound Care Businesses: Key Trends in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC businessIn the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported revenue of $1.09 billion, reflecting YoY

  • Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1
    Market Realist2 days ago

    Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performance In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide

  • What Are Analysts Recommending for Johnson & Johnson?
    Market Realist2 days ago

    What Are Analysts Recommending for Johnson & Johnson?

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Stock price movementsOn April 17, Johnson & Johnson (JNJ) closed at $138.52, 0.36% higher than its previous closing price, 16.78% higher than its

  • JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs
    Market Realist2 days ago

    JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) fall of 20.6% on

  • JNJ Surpassed Consensus Estimates in the First Quarter
    Market Realist2 days ago

    JNJ Surpassed Consensus Estimates in the First Quarter

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?Revenue performance Johnson & Johnson (JNJ) reported its earnings results for the first quarter of 2019 on April 16. In its first-quarter earnings press release, the company

  • Miguel Patricio: 10 Things to Know About the New Kraft Heinz CEO
    InvestorPlace2 days ago

    Miguel Patricio: 10 Things to Know About the New Kraft Heinz CEO

    There's a new Kraft Heinz CEO that will be leading the company in the near future.Here's what we know about the new CEO for Kraft Heinz (NASDAQ:KHC). * The new Kraft Heinz CEO is Miguel Patricio. * He will be taking over as the CEO of the company starting on July 1, 2019. * This will have him taking over the position from Bernardo Hees, who will remain with the company as its CEO until June, 30, 2019. * Patricio is joining the company as the new Kraft Heinz CEO after spending two decades with Anheuser-Busch InBev (NYSE:BUD). * During his time with Anheuser-Busch InBev, Patricio served in various roles as part of its Executive Leadership team. * These roles include him serving as the company's Global Chief Marketing Officer from 2012 to 2018. * Prior to his, he was serving as the President of Asia Pacific from 2008 to 2012 for Anheuser-Busch InBev. * Before serving in that role, he was the President of North America for Anheuser-Busch InBev from 2006 to 2008. * Before starting his career at Anheuser-Busch InBev, Patricio worked at several other consumer companies. * Among these companies are Philip Morris (NYSE:PM), Coca-Cola (NYSE:KO) and Johnson & Johnson (NYSE:JNJ). * 7 Tech Stocks With Too Much Risk, Not Enough Upside You can follow this link to learn more about new Kraft Heinz CEO Miguel Patricio and the experience he is bringing to the company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsKHC stock started the day off up 1% on Monday morning, but is now largely unmoved as of the afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Miguel Patricio: 10 Things to Know About the New Kraft Heinz CEO appeared first on InvestorPlace.

  • Benzinga2 days ago

    6 Cannabis Execs On The Strengths Of Their Businesses

    Vertical Companies is among the largest vertically integrated businesses within the legal medical cannabis industry. The company is focused on "doing all things with the plant" except for operating a retail presence, said CEO Smoke Wallin.

  • JNJ or PFE: Comparing Their Fastest-Growing Immunology Drugs
    Market Realist2 days ago

    JNJ or PFE: Comparing Their Fastest-Growing Immunology Drugs

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of

  • JNJ or PFE: Which Has Better EPS Guidance for 2019?
    Market Realist2 days ago

    JNJ or PFE: Which Has Better EPS Guidance for 2019?

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)EPS guidance In its first-quarter earnings press release, Johnson & Johnson (JNJ) raised the guidance for its adjusted diluted operational EPS from its

  • Johnson & Johnson posts strong revenue in 1Q
    Associated Press3 days ago

    Johnson & Johnson posts strong revenue in 1Q

    Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson's first-quarter profit down 14%, but the health care giant beat profit and revenue expectations, pushing up its ...

  • Asian shares edge lower despite encouraging China GDP data
    Associated Press3 days ago

    Asian shares edge lower despite encouraging China GDP data

    Major share benchmarks were mostly lower in Asia on Wednesday after China announced its economy grew at a 6.4% annual pace in the last quarter. Japan's Nikkei 225 index gained 0.3% to 22,289.32 and the ...

  • Financial Times3 days ago

    Revamp at Silence does little to improve investors’ wellbeing

    Silence is more “of the lambs” than golden at Aim-quoted Silence Therapeutics. Shares in the biotechnology company, which is backed by an array of high-profile institutional investors including Woodford and Invesco, have fallen from close to 250p to 58p in 18 months. Last August, Annalisa Jenkins quit after being chairwoman for 10 months.

  • 5 Top Pharmaceutical Stocks to Buy in 2019
    Motley Fool5 days ago

    5 Top Pharmaceutical Stocks to Buy in 2019

    Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

  • The Top 10 Biotechnology Companies (JNJ, ROG.VX)
    Investopedia6 days ago

    The Top 10 Biotechnology Companies (JNJ, ROG.VX)

    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

  • TheStreet.com6 days ago

    Be Careful With Healthcare Stocks Here

    CEO David Wichmann on his company's earnings conference call Tuesday: "Medicare For All." UNH shares had been bid up in Tuesday morning trade on the back of earnings and revenues that exceeded analyst estimates. Want to be alerted before Jim Cramer buys or sells JNJ or UNH?

  • Benzinga6 days ago

    Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

    Zoom Technologies Inc (OTC: ZOOM ) traded higher by as much as 120 percent Thursday morning after popular video and audio platform Zoom Video Communications Inc (NASDAQ: ZM ) held its highly anticipated ...